SAN DIEGO, Oct. 16 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc. will be presenting at the BIO InvestorForum 2006 on Thursday, October 19, 2006 at 10:00 AM Pacific Daylight Time. Mike Grey, president and chief executive officer of SGX Pharmaceuticals, will provide a corporate overview including an update on the Company’s oncology pipeline. The conference is being held October 18-19 at the Palace Hotel in San Francisco, California.
A live webcast of the presentation will be available under the investor relations section of the Company’s website at www.sgxpharma.com. Replays of the presentation will be available for 90 days following the event. Please connect to the Company’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About SGX Pharmaceuticals
SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. SGX’s oncology pipeline includes Troxatyl as well as drug candidates from its enabling, proprietary FAST(TM) drug discovery platform, including next generation BCR-ABL inhibitors currently being developed in partnership with Novartis, and MET tyrosine kinase inhibitors. Pending successful completion of certain preclinical studies, the Company anticipates nominating a development candidate within the BCR-ABL program before the end of 2006 and filing an Investigational New Drug application and initiating a Phase I clinical study in the third quarter of 2007. The Company also anticipates selecting a development candidate in its MET program in the third quarter of 2007. More information on the pipeline and drug discovery platform can be found at www.sgxpharma.com and in the Company’s various filings with the Securities and Exchange Commission.
SGX Pharmaceuticals Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to future plans and expectations regarding the BCR-ABL and MET programs. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery and development. For a discussion of these and other factors, please refer to the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2005 as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
SGX Pharmaceuticals, Inc.
CONTACT: Todd Myers, Chief Financial Officer of SGX Pharmaceuticals, Inc.,+1-858-558-4850; or Jason Spark, Media & Investor Relations of PorterNovelli Life Sciences, +1-619-849-6005, for SGX Pharmaceuticals, Inc.
Web site: http://www.sgxpharma.com/
